Overview
Berberine ursodeoxycholate represents a new molecular entity that offers the possibility of combination therapy for chronic metabolic and liver diseases in a single treatment.
This lead compound, an investigational drug currently under evaluation in clinical studies, is a potential first-in-class orally administered gut-liver anti-inflammatory metabolic modulator, providing a dual mechanism of action with the potential to treat the core aspects of chronic metabolic diseases and liver diseases.
Our priority in the clinic is advancing our lead candidate, berberine ursodeoxycholate (HTD1801), in chronic metabolic and liver diseases driven by insulin resistance and chronic inflammation.
| Therapeutic Area | Planning | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|
MASH | Phase 2b (Centricity) | Results 1H2025 | |||
| Phase 2b (Centricity) Read Less | |||||
T2DM | Phase 3 (Symphony 1) | Results 1H2025 | |||
| Phase 3 (Symphony 1) Read Less | |||||
T2DM | Phase 3 (Symphony 2) | Results 1H2025 | |||
| Phase 3 (Symphony 2) Read Less | |||||
T2DM | Phase 3 (Harmony) | Results 2H2025 | |||
| Phase 3 (Harmony) Read Less | |||||
Obesity | monotherapy or add-on to GLP-1 RA | Phase 2 ready | |||
| monotherapy or add-on to GLP-1 RA Read Less | |||||
PSC | Phase 3 ready | ||||
Read Less | |||||
SHTG | Phase 2 ready | ||||
Read Less | |||||
| Therapeutic Area | Status | Phase |
|---|---|---|
MASH |
Results 1H2025 | Phase 2 Phase 2b (Centricity) |
| Phase 2b (Centricity) Read Less | ||
T2DM |
Results 1H2025 | Phase 3 Phase 3 (Symphony 1) |
| Phase 3 (Symphony 1) Read Less | ||
T2DM |
Results 1H2025 | Phase 3 Phase 3 (Symphony 2) |
| Phase 3 (Symphony 2) Read Less | ||
T2DM |
Results 2H2025 | Phase 3 Phase 3 (Harmony) |
| Phase 3 (Harmony) Read Less | ||
Obesity |
Phase 2 ready | Planning monotherapy or add-on to GLP-1 RA |
| monotherapy or add-on to GLP-1 RA Read Less | ||
PSC |
Phase 3 ready | Phase 2 |
Read Less | ||
SHTG |
Phase 2 ready | Phase 1 |
Read Less | ||